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Abstract
Background: Human leukocyte antigen (HLA) alleles are associated with many autoimmune diseases, including
anti-glomerular basement membrane (GBM) disease. In our previous study, it was demonstrated that HLA-
DRB1*1501 was strongly associated with anti-GBM disease in Chinese. However, the association of anti-GBM disease
and other HLA class II genes, including HLA-DQB1, -DQA1,-DPB1 alleles, has rarely been investigated in Asian,
especially Chinese patients. The present study further analyzed the association between anti-GBM disease and HLA-
DQB1, -DQA1, and -DPB1 genes. Apart from this, we tried to locate the potential risk amino acid residues of anti-
GBM disease.
Methods: This study included 44 Chinese patients with anti-GBM disease and 200 healthy controls. The clinical and
pathological data of the patients were collected and analyzed. Typing of HLA-DQB1, -DQA1 and -DPB1 alleles were
performed by bi-directional sequencing of exon 2 using the SeCoreTM Sequencing Kits.
Results: Compared with normal controls, the prevalence of HLA-DPB1*0401 was significantly lower in patients with
anti-GBM disease (3/88 vs. 74/400, p = 4.4 × 10-4, pc = 0.039). Comparing with normal controls, the combination of
presence of DRB1*1501 and absence of DPB1*0401 was significantly prominent among anti-GBM patients (p = 2.0
× 10-12, pc = 1.7 × 10-10).
Conclusions: HLA-DPB1*0401 might be a protective allele to anti-GBM disease in Chinese patients. The combined
presence of DRB1*1501 and absence of DPB1*0401 might have an even higher risk to anti-GBM disease than HLA-
DRB1*1501 alone.
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Background
Anti-glomerular basement membrane (GBM) disease,
defined by the presence of autoantibodies in the circula-
tion against a3 chain non-collagen 1 domain of type IV
collagen [a3(IV)NC1] [1], is a severe autoimmune dis-
ease. It manifests as rapidly progressive glomerulone-
phritis; when accompanied by alveolar hemorrhage, it is
termed Goodpasture’s disease.
Human leukocyte antigen (HLA) alleles, located on
the short arm of chromosome 6, have been well known
to be associated with most autoimmune diseases [2].
HLA genes encode numerous molecules including the
HLA class I and II molecules, which have immunologi-
cal functions. It was reported that anti-GBM disease was
positively associated with HLA-DRB1*1501 and nega-
tively associated with HLA-DRB1*07 in Caucasian popu-
lation [3]. In Asian populations, HLA-DRB1*1501 was
also considered as a risk allele for Japanese [4] and Chi-
nese patients [5]. These data suggested that HLA-
DRB1*1501 is a common risk allele for anti-GBM dis-
ease in various populations. However, the association of
anti-GBM disease and HLA class II genes, including
HLA-DRB1, -DQB1, -DQA1, and -DPB1 alleles, has
rarely been investigated in Asian, especially Chinese
patients [4,5]. Since our previous study has located the
risk allele of HLA-DRB1 [5], to better understand the
* Correspondence: leimeng@public3.bta.net.cn
Renal Division, Department of Medicine, Peking University First Hospital;
Institute of Nephrology, Peking University; Key Laboratory of Renal Disease,
Ministry of Health of China; Beijing 100034, China
Luo et al. BMC Nephrology 2011, 12:21
http://www.biomedcentral.com/1471-2369/12/21
© 2011 Luo et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
genetic background of this disease and prepare for the
study at the level of peptide, in the current study, we
further investigated the distribution and clinical associa-
tion of HLA-DQB1, -DQA1 and -DPB1. Moreover, we




Forty-four patients with anti-GBM disease, who were
diagnosed at Renal Division, Peking University First
Hospital, from 1996 to 2007, were included in this
study. Anti-GBM disease was defined as the patient had
glomerulonephritis and/or pulmonary hemorrhage, and
patient’s serum contained circulating anti-GBM antibo-
dies [6]. The onset of the disease was judged by renal or
extra-renal signs and symptoms of anti-GBM disease, or
abnormalities related to anti-GBM disease were detected
by various examinations, including hemoptysis, oliguria
or anuria, hematuria or elevated serum creatinine [6,7].
All the 44 patients received renal biopsy. Clinical and
pathological data were collected at the time of renal
biopsy. Two hundred ethnically matched healthy blood
donors were employed as normal controls. The research
was in compliance of the declaration of Helsinki and
approved by the ethic committee of the local hospital.
Informed consent was obtained from each patient.
Detection of serum anti-GBM autoantibodies
Anti-GBM autoantibodies were measured by ELISA
using bovine a(IV)NC1 as the solid phase antigen,
which was described previously [8]. The results were
expressed as relative absorbance value to a percentage
of a known positive control serum, and values greater
than 13% were regarded as positive.
Samples
Peripheral blood samples (10 ml) from patients with
anti-GBM disease and normal controls were collected in
EDTA. Genomic DNA was obtained from peripheral
blood leukocytes with a salting-out procedure [9].
Sequence based typing
Typing of HLA-DQB1, -DQA1 and -DPB1 alleles were
performed by bi-directional sequencing of exon 2 using
the SeCoreTM Sequencing Kits (Invitrogen, Brown
Deer, WI, USA).
Statistical analysis
The difference in the frequencies of HLA alleles in dis-
ease samples and controls was compared using the Chi-
square test or Fisher’s exact test as appropriate. To com-
pare the HLA alleles of subjects stratified by various
demographic and clinical parameters, Chi-square test,
Fisher’s exact test, or nonparametric test was used as
appropriate. Bonferroni correction was applied to correct
p-value (p corrected, pc). It was considered significant
difference if the pc value was less than 0.05. The statisti-
cal analysis was performed in SPSS statistical software
package (version 11.0, Chicago, Ill, USA). The evaluation
at the amino acid level including the examination of
polymorphic amino acid residue, pocket of amino acid,
zygosity and tests for association, interaction, and linkage
disequilibrium among amino acid epitopes of the same
HLA molecule or between HLA isotypes were conducted
by SKDM software program [10].
Results
Demographic and clinicopathological features
Among the 44 patients with anti-GBM disease, 30 were
male and 14 were female. The median age of the 44
patients was 27 (range 13-82) years old on diagnosis. Six-
teen out of 44 patients had pulmonary hemorrhage. All
of the patients had hematuria and proteinuria. 17/44
(38.6%) patients had anuria or oliguria. On diagnosis, the
level of serum creatinine was 765.4 ± 388.7 μmol/L.
Renal biopsy was performed in all the 44 patients. 41/44
(93.8%) patients had crescent formation in more than
50% of the glomeruli and 30 (68.2%) had crescent forma-
tion in more than 85% of the glomeruli in the renal speci-
men. Direct immunofluorescence examination was
performed in 35 cases. All of them showed linear or fine
granular IgG and/or C3 deposition along glomerular
capillary wall. Outcome data were available for 40 out of
the 44 patients. At the end of one year after diagnosis,
only 7/40 (17.5%) patients were dialysis-independent, and
33/40 (82.5%) patients were dialysis-dependent or died.
HLA-DQB1, -DQA1 and -DPB1 alleles and their association
with anti-GBM disease
The frequencies of each HLA-DQB1, -DQA1 and -DPB1
allele for the 44 patients with anti-GBM disease and 200
ethnically matched healthy controls were determined by
sequence based typing. A total of 9 HLA-DQB1 alleles, 9
HLA-DQA1 and 34 HLA-DPB1 alleles typed in our study.
Compared with normal controls, the prevalence of HLA-
DPB1*0401 was significantly lower in patients with anti-
GBM disease (3/88 vs. 74/400, p = 4.4 × 10-4, pc = 0.039)
(Table 1). However, the age (transformed by log10) of
HLA-DPB1*0401 positive patients was significantly
younger than that of DPB1*0401 negative patients (p =
0.011). Besides, the proportion of patients having hemop-
tysis was significantly higher in patients with DPB1*0401
than that in patients without DPB1*0401 (p = 0.042)
(Table 2). There was no significant difference between
these patients and normal controls on other HLA alleles.
No significant difference of gender, age, level of anti-GBM
autoantibodies, serum creatinine, or other clinical and
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n × 2 = 88
Normal
controls
n × 2 = 400




n × 2 = 88
Normal
controls
n × 2 = 400
p pc OR 95% CI
DQB1*0201 17 95 0.37 0.77 0.43-
1.37
DPB1*0801 3 1 0.02 1.76 14.08 1.45-
137.03
DQB1*0301 15 45 0.13 1.62 0.86-
3.06
DPB1*0901 4 3 0.022 1.94 6.3 1.39-
28.68
DQB1*0302 2 13 1 0.69 0.15-
3.12
DPB1*1101 0 1 1
DQB1*0303 7 39 0.6 0.8 0.35-
1.85
DPB1*1301 4 5 0.06 3.76 0.99-
14.31
DQB1*0401 2 8 0.7 1.14 0.24-
5.46
DPB1*1302 0 1 1
DQB1*0501 13 45 0.36 1.37 0.70-
2.66
DPB1*1601 1 4 1 1.14 0.13-
10.31
DQB1*0502 3 24 0.44 0.55 0.16-
1.88
DPB1*1602 0 1 1
DQB1*0503 8 37 0.96 0.98 0.44-
2.19
DPB1*1701 0 3 1
DQB1*0602 21 94 0.94 1.02 0.59-
1.75
DPB1*1801 1 7 1 0.65 0.078-
5.31
DQA1*0101 1 17 0.22 0.26 0.034-
1.97
DPB1*2001 2 4 0.3 2.3 0.42-
12.77
DQA1*0102 19 148 0.006 0.53 0.47 0.27-
0.81
DPB1*2002 0 2 1
DQA1*0103 2 12 1 0.75 0.17-
3.42
DPB1*2101 0 1 1
DQA1*0201 16 36 0.011 0.97 2.25 1.18-
4.27
DPB1*2301 0 3 1
DQA1*0301 26 92 0.19 1.4 0.84-
2.35
DPB1*2401 0 3 1
DQA1*0302 3 3 0.075 4.67 0.93-
23.54
DPB1*2402 3 5 0.16 2.79 0.65-
11.89
DQA1*0401 1 12 0.48 0.37 0.048-
2.90
DPB1*2601 3 4 0.11 3.49 0.77-
15.90
DQA1*0501 19 70 0.37 1.3 0.73-
2.29
DPB1*3301 13 44 0.32 1.4 0.72-
2.73
DQA1*0601 1 10 0.7 0.45 0.057-
3.55
DPB1*3501 0 3 1
DPB1*0101 1 6 1 0.76 0.090-
6.35
DPB1*4001 1 0 0.18
DPB1*0201 24 98 0.59 1.16 0.69-
1.95
DPB1*4501 0 3 1
DPB1*0301 8 29 0.56 1.28 0.56-
2.90
DPB1*4801 0 1 1
DPB1*0302 1 3 0.55 1.52 1.16-
14.80
DPB1*5201 0 1 1




DPB1*5401 0 1 1
DPB1*0402 15 82 0.46 0.8 0.44-
1.46
DPB1*5701 0 2 1
DPB1*0601 1 2 0.45 2.29 2.21-
25.51
DPB1*6601 0 1 1
DPB1*0602 0 1 1 DPB1*8601 0 1 1
[Abbreviations] pc, P corrected; OR, odds ratio; CI, confident interval.
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pathological parameters was found between anti-GBM
patients with and without HLA-DPB1*0401 (Table 2).
The combined analysis of HLA-DRB1 and -DPB1 alleles
When we analyzed our HLA-DPB1 typing data together
with HLA-DRB1 typing data from our previous study
[5], we found that 2 patients and 19 controls had both
HLA-DRB1*1501 and DPB1*0401 present. For those
characterized by the combined presence of DRB1*1501
and absence of DPB1*0401, 32 patients and 39 controls
were identified. Comparing with controls, the prevalence
of this combination was extremely prominent among
anti-GBM patients (p = 2.0 × 10-12, pc = 1.7 × 10-10,
OR = 11.01, 95% CI 5.2-23.31).
The evaluation at the amino acid level
Significant residue was found neither for HLA-DRB1 nor
in HLA-DRB1 pockets. For HLA-DPB1, its productions
phenylalanine at position 35 (DPB1_F-35) and lysine at
position 69 (DPB1_K-69) were observed in decreased fre-
quencies among anti-GBM disease, but their difference
was not significant after correction (Table 3). Besides, the
evaluations of pocket residues, zygosity analysis and
interaction analysis about DPB1_F-35 and K-69 found no
significant difference between patients and controls.
Discussion
The current study analyzed the distribution of HLA
class II alleles in patients with anti-GBM disease and
their potential significance. For HLA class II loci, HLA-
DRB1 and -DPB1 encode relatively more variable gene
products for HLA-DR and -DP molecules respectively,
while both HLA-DQB1 and -DQA1 are variable in
human population. Besides, previous studies have
located some HLA-DRB1, -DQB1 and -DPB1 alleles
with association with anti-GBM disease in Caucasian as
well as Asian population [5,11,12]. But in Chinese
patients, few studies have been done in this topic [5].
Therefore, we choose to type HLA-DQB1, -DQA1 and
-DPB1 loci in this study, on the basis of our previous
study on HLA-DRB1 [5].
Our typing results indicated that HLA-DPB1*0401
might be non-predisposing on anti-GBM disease. We
stratified by the presence of DPB1*0401 on patients
with anti-GBM disease and tried to investigate how this
allele has its protective influence on clinical and patho-
logical characteristics of patients. However, we found
that patients with HLA-DPB1*0401 were younger and
were more likely to have hemoptysis. Since there were
only three patients with positive HLA-DRB1*0401, larger
sample size is needed to investigate the association
between this allele and the disease.
Our previous study [5] has located HLA-DRB1*1501
as a risky allele to anti-GBM disease in the same popu-
lation. When we analyzed the combined presence of
DRB1*1501 and absence of DPB1*0401, we found this
combination had an even higher risk to anti-GBM dis-
ease (p = 2.0 × 10-12) than HLA-DRB1*1501 alone (p =
1.6 × 10-7). To further investigate how these alleles have
their influence on disease, we used SKDM software to
evaluate their productions at amino acid level. However,
no amino acid with significant difference was found by
this evaluation. Since little is known about the relation
between HLA-DP and HLA-DR, it is difficult to know
Table 2 Clinical and pathological characteristics of patients with anti-GBM disease, categorized by the presence of
HLA gene
DPB1*0401
positive negative p value
Gender (male/female) 1/2 29/12 0.23
Age (transformed by log10), mean ± standard deviation 1.37 ± 0.05 1.50 ± 0.19 0.011
Level of anti-GBM antibodies (%), mean ± standard deviation 71.53 ± 61.58 81.43 ± 46.63 0.73
Hemoptysis 3/3 13/41 0.042
Oliguria or anuria 1/3 16/41 1.00
Interval between onset and diagnosis (days), mean ± standard deviation 68.33 ± 31.34 62.87 ± 52.83 0.86
Scr (μmol/L), mean ± standard deviation 1024.33 ± 362.41 746.49 ± 387.91 0.24
Percentage of crescents in glomeruli, median (1st and 3rd quartile) 100 (87.5, 100) 94.87 (67.69, 100) 0.45
Dialysis-dependent or died 3/3 31/37 1.00
[Abbreviations] Scr: serum creatinine.
Table 3 Evaluation at the amino acid level by SKDM
HLA-DPB1 Residues
Alls Pos AA Assoc p pc OR
0401 35 F - 0.031 1 0.04
0401 69 K - 0.0067 0.31 0.28
HLA-DPB1 Pocket Residues pc
Pocket 4 (Pos:13,69,76,68,72,24) 0.17
Pocket 7 (Pos: 26,59,69,45,65) 0.17
Pocket 9 (Pos: 9,58,55,35,36) 0.83
[Abbreviations] Alls, alleles; Pos, position; AA, amino acid; Assoc, association;
pc, P corrected; OR, odds ratio; F, phenylalanine; K, lysine.
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how these two alleles interact with each other on mole-
cular level in the pathogenesis of anti-GBM disease.
Previous studies have focused on association between
HLA-DR and -DQ genes and their haplotype with anti-
GBM disease [3,11,12]. The single allele DQB1*0302,
haplotypes DQB1*0602-DRB1*1501 and DQB1*0201-
DRB1*0301 were identified as risk alleles [3,11,12], while
HLA-DQB1*0501 was considered as a protective allele
[3,12]. However, these potential associations were not
observed in our study. Actually, no HLA-DQ allele was
found to be significantly associated with patients with
anti-GBM disease in our study.
HLA class II alleles have been demonstrated a connec-
tion with many autoimmune diseases [13-15]. Neverthe-
less the mechanism underneath is still unknown. HLA
association in anti-GBM disease is believed to reflect the
ability of certain class II molecules to bind and present
peptides derived from the autoantigen to T helper cells
[12]. Although at amino acid level, our study showed no
significance, theories from other studies may offer us
some clues. As far as we have known, the strong positive
association with DRB1*1501 [4,5,11,12] as well as negative
associations with DRB1*01 and DRB1*07 [3] were found
[12,16,17] in many studies. According to above findings,
Phelps et al. [17] suggested that DR1/7 (encoded by
DRB1*01/07) could protect by capturing a3(IV)NC1 pep-
tides and preventing their display bound to DR15. Judging
from this, we speculate that the similar protective mechan-
ism might happen to HLA-DPB1*0401. We suppose that
the beta chain of HLA-DP produced by DPB1*0401 pre-
vents peptide such as a3(IV)NC1 from binding DR15,
which leads to the disease. Nonetheless, the exact mechan-
ism requires further research to confirm.
Conclusions
In conclusion, HLA-DPB1*0401 might be a protective
allele to anti-GBM disease in Chinese patients. The
combined presence of DRB1*1501 and absence of
DPB1*0401 might have an even higher risk to anti-GBM
disease than HLA-DRB1*1501 alone.
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